-
JBCRG-05
Phase II study of Letrozole and Docetaxel as preoperative chemotherapy in postmenopausal/hormone receptor positive / neo-adjuvant anthracycline refractory primary breast cancer
- Status
-
Study Closed
- Objectives
-
Evaluation of the response rate, the pathological response and the safety of neoadjuvant Letrozole combined with Docetaxel x 4 courses for postmenopausal women with hormone receptor positive, operable and primary breast cancer which confirmed SD or PD in prior anthracycline-containing chemotherapy.
- Subjects
-
- Endpoints
-
Primary Outcome: Response rate, Secondary Outcomes: Pathological CR rate, Breast Conserving Surgery rate, Safety, Disease-free survival and Overall survival
- Trial Period
-
August 2007 - February 2015 (Registration: 2.5 years, Follow-up study: 5 years)
- Lead Principal Investigator
-
Takahiro Nakayama (Osaka Medical Center for Cancer and Cardiovascular Disease)
- Target Sample Size
-
33
- Regimen
-
Doc75 q3w x4->Letrozole 12(-18)w
- Source of Funding
-
Japan Breast Cancer Research Group (JBCRG)
- Conference Presentation
-
- Articles and Publications
-
- UMIN-ID
-
- jRCT
-
UMIN000001214
- Memo
-
- COI Disclosure
-
